Abstract:BackgroundLung adenocarcinoma (LUAD) is a major subtype of non-small cell lung cancer (NSCLC) with a highly heterogeneous tumor microenvironment. Immune checkpoint inhibitors (ICIs) are more effective in tumors with a pre-activated immune status. However, the potential of the immune activation-associated gene (IAG) signature for prognosis prediction and immunotherapy response assessment in LUAD has not been established. Therefore, it is critical to explore such gene signatures.MethodsRNA sequencing profiles and corresponding clinical parameters of LUAD were extracted from the TCGA and GEO databases. Unsupervised consistency clustering analysis based on immune activation-related genes was performed on the enrolled samples. Subsequently, prognostic models based on genes associated with prognosis were built using the last absolute shrinkage and selection operator (LASSO) method and univariate Cox regression. The expression levels of four immune activation related gene index (IARGI) related genes were validated in 12 pairs of LUAD tumor and normal tissue samples using qPCR. Using the ESTIMATE, TIMER, and ssGSEA algorithms, immune cell infiltration analysis was carried out for different groups, and the tumor immune dysfunction and rejection (TIDE) score was used to evaluate the effectiveness of immunotherapy.ResultsBased on the expression patterns of IAGs, the TCGA LUAD cohort was classified into two clusters, with those in the IAG-high pattern demonstrating significantly better survival outcomes and immune cell infiltration compared to those in the IAG-low pattern. Then, we developed an IARGI model that effectively stratified patients into different risk groups, revealing differences in prognosis, mutation profiles, and immune cell infiltration within the tumor microenvironment between the high and low-risk groups. Notably, significant disparities in TIDE score between the two groups suggest that the low-risk group may exhibit better responses to ICIs therapy. The IARGI risk model was validated across multiple datasets and demonstrated exceptional performance in predicting overall survival in LUAD, and an IARGI-integrated nomogram was established as a quantitative tool for clinical practice.ConclusionThe IARGI can serve as valuable biomarkers for evaluating the tumor microenvironment and predicting the prognosis of LUAD patients. Furthermore, these genes probably provide valuable guidance for establishing effective immunotherapy regimens for LUAD patients.

Identification of a coagulation‐related signature correlated with immune infiltration and their prognostic implications in lung adenocarcinoma

Integrated Single-Cell and Transcriptome Sequencing Analyses Determines a Chromatin Regulator-Based Signature for Evaluating Prognosis in Lung Adenocarcinoma.

Application of Cytochrome C-Related Genes in Prognosis and Treatment Prediction of Lung Adenocarcinoma

Identification of Inflammatory Response-Related Gene Signature Associated With Immune Status and Prognosis of Lung Adenocarcinoma

Identification of cuproptosis and immune-related gene prognostic signature in lung adenocarcinoma

Integrated Analysis of Cell Cycle–Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma

Identification of a Risk Signature and Immune Cell Infiltration Based on Extracellular Matrix-Related Lncrnas in Lung Adenocarcinoma.

Identification of prognostic candidate signatures by systematically revealing transcriptome characteristics in lung adenocarcinoma with differing tumor microenvironment immune phenotypes

Development of an Immune-Related Risk Signature for Predicting Prognosis in Lung Squamous Cell Carcinoma

Identification of an immune prognostic 11-gene signature for lung adenocarcinoma

Identification of an inflammatory response signature associated with prognostic stratification and drug sensitivity in lung adenocarcinoma

A Novel Immune-Related Gene Signature Predicts Prognosis of Lung Adenocarcinoma

An Immune Panel Signature Predicts Prognosis of Lung Adenocarcinoma Patients and Correlates with Immune Microenvironment

A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma

Comprehensive analysis of cuproptosis-related genes in immune infiltration and prognosis in lung adenocarcinoma

Identification and Validation of Immune-Related LncRNA Prognostic Signature for Lung Adenocarcinoma

Development and validation of an immune-related gene signature for prognosis in Lung adenocarcinoma.

A novel cuproptosis-related signature predicts prognosis and immunotherapy efficacy in lung adenocarcinoma

Identification of Immune Activation-Related Gene Signature for Predicting Prognosis and Immunotherapy Efficacy in Lung Adenocarcinoma

Prognostic value and immunological function of cuproptosis-related genes in lung adenocarcinoma

Exploring a new signature for lung adenocarcinoma: analyzing cuproptosis-related genes through Integrated single-cell and bulk RNA sequencing